MedPath

Hyaluronic acid

Generic Name
Hyaluronic acid
Drug Type
Small Molecule
Chemical Formula
C28H44N2O23
CAS Number
9004-61-9
Unique Ingredient Identifier
S270N0TRQY

Overview

Hyaluronic acid (HA) is an anionic, nonsulfated glycosaminoglycan found in connective, epithelial, and neural tissues; it was first isolated in 1934. Karl Meyer and John Palmer obtained glycosaminoglycan (GAG) from the bovine eye, giving it the name “hyaluronic acid”. HA is involved in many important physiological processes, including but not limited to wound healing, tissue regeneration, and joint lubrication. It demonstrates unique viscoelasticity, moisturizing, anti-inflammatory qualities, and other important properties that prove beneficial in various clinical applications. HA is used in drug delivery systems for the treatment of cancer, ophthalmological conditions, joint conditions, and aesthetic imperfections. Several preparations of hyaluronic acid have been approved by the FDA and are available in oral, topical, and injectable forms. A popular use of hyaluronic acid in recent years is cosmetic injection due to its ability to minimize the appearance of wrinkles and aging-related skin imperfections.

Background

Hyaluronic acid (HA) is an anionic, nonsulfated glycosaminoglycan found in connective, epithelial, and neural tissues; it was first isolated in 1934. Karl Meyer and John Palmer obtained glycosaminoglycan (GAG) from the bovine eye, giving it the name “hyaluronic acid”. HA is involved in many important physiological processes, including but not limited to wound healing, tissue regeneration, and joint lubrication. It demonstrates unique viscoelasticity, moisturizing, anti-inflammatory qualities, and other important properties that prove beneficial in various clinical applications. HA is used in drug delivery systems for the treatment of cancer, ophthalmological conditions, joint conditions, and aesthetic imperfections. Several preparations of hyaluronic acid have been approved by the FDA and are available in oral, topical, and injectable forms. A popular use of hyaluronic acid in recent years is cosmetic injection due to its ability to minimize the appearance of wrinkles and aging-related skin imperfections.

Indication

The intra-articular preparations of hyaluronic acid are indicated for knee pain associated with osteoarthritis. Hyaluronic acid is used in cosmetic applications to prevent and reduce the appearance of wrinkles on the face, and as a dermal filler to correct facial imperfections or other imperfections on other parts of the body. It is frequently an ingredient in topical applications for wound healing and symptomatic treatment of skin irritation from various causes. Hyaluronic acid may also be indicated in ophthalmological preparations or oral capsules to treat discomfort caused by dry eyes or conjunctivitis and for its protective qualities during and before eye surgery. Finally, hyaluronic acid can be used off-label to coat the bladder for relief of interstitial cystitis symptoms.

Associated Conditions

  • Actinic Keratosis (AK)
  • Burns
  • Chronic Skin Ulcers
  • Conjunctivitis
  • Dehydration
  • Dermabrasion
  • Dermatosis
  • Dry Eyes
  • Facial Defect
  • Interstitial Cystitis
  • Keratoconjunctivitis
  • Ocular Irritation
  • Osteoarthritis (OA)
  • Pain of the knee
  • Seasonal Allergic Conjunctivitis
  • Skin Burn
  • Skin Irritation
  • Skin fissures
  • Tissue Adhesions
  • Varicose Ulcers
  • Wound
  • Eye discomfort
  • Facial fine wrinkling
  • Sensation of burning in the eyes
  • Superficial Wounds

FDA Approved Products

HYALURONIC ACID SODIUM SALT 2% / MOMETASONE FUROATE 0.1% / NIACINAMIDE 4%
Manufacturer:Sincerus Florida, LLC
Route:TOPICAL
Strength:2 g in 100 g
Approved: 2019/05/21
NDC:72934-2098
HYALURONIC ACID SODIUM SALT 0.5% / NIACINAMIDE 4% / TRETINOIN 0.1%
Manufacturer:Sincerus Florida, LLC
Route:TOPICAL
Strength:0.5 g in 100 g
Approved: 2019/04/23
NDC:72934-2092
HYALURONIC ACID SODIUM SALT 0.5% / NIACINAMIDE 4% / TRETINOIN 0.025%
Manufacturer:Sincerus Florida, LLC
Route:TOPICAL
Strength:0.5 g in 100 g
Approved: 2019/04/23
NDC:72934-2090
Hyaluronic Acid
Manufacturer:Quimfa S.A
Route:INTRAEPIDERMAL
Strength:2.5 g in 1 1
Approved: 2020/06/05
NDC:77651-4162
HYALURONIC ACID SODIUM SALT 1% / NIACINAMIDE 4% / TACROLIMUS 0.1%
Manufacturer:Sinceru Florida, LLC
Route:TOPICAL
Strength:1 g in 100 g
Approved: 2019/04/24
NDC:72934-2096

Singapore Approved Products

HYALGAN INJECTION 20 mg/2 ml
Manufacturer:FIDIA FARMACEUTICI S.P.A
Form:INJECTION
Strength:20 mg/2 ml
Online:Yes
Approved: 1991/06/22
Approval:SIN06242P
NEPHROSTERIL FOR INTRAVENOUS INFUSION
Manufacturer:FRESENIUS KABI AUSTRIA GMBH
Form:INJECTION
Strength:1.5 g/l
Online:Yes
Approved: 1991/06/21
Approval:SIN06299P

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath